KAPA · Kairos Pharma, LTD. · Analyst Estimates
$0.56
+0.01 (+2.67%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.84M
Shares
3.39M
Volume · Oct 23
112.9K
Avg daily vol (38 sessions)
568.46K
Analyst Estimates
Compare analyst forecasts for Kairos Pharma, LTD. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 07:01 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.37
|
-0.37
|
-0.37
|
1
|
-0.37
|
-0.37
|
-0.37
|
-0.38
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
2
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.67
|
-0.67
|
-0.67
|
1
|
-0.67
|
-0.67
|
-0.67
|
-0.55
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.09
|
-0.09
|
-0.09
|
1
|
-0.09
|
-0.09
|
-0.09
|
-0.09
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.11
|
-0.11
|
-0.11
|
1
|
-0.11
|
-0.11
|
-0.11
|
-0.12
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
2
|
— | — | — | — | — | — | — | — |